Evolving overdose crisis shakes previously effective treatments

“You can’t inject a horse tranquilizer and think nothing bad is gonna happen” to you, said Ty Sears, 33, a longtime drug user now in recovery.

Hims’ push into compounded GLP-1 drugs risks scrutiny from Novo Nordisk

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) The digital health company Hims & Hers

May 22, 2024

Biosynth’s unique online custom peptide toolset completed with full order tracking and QC data portal

Biosynth, a supplier of critical raw materials and services for diagnostics, vaccines, and pharmaceuticals, is pleased to announce the next step in its custom peptide

June 28, 2024

Lawmakers urge U.S. Patent Office and drugmakers to correct patent mistakes

A group of lawmakers wants the U.S. Patent & Trademark Office and drug companies to change their approach toward handling mistakes in disclosing patent terms,

September 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.